MONTSERRAT
MARTINEZ ALONSO
CON
![Foto de MONTSERRAT](/img/nophoto.png)
![Foto de GlaxoSmithKline (United Kingdom)](/img/noimage_org.png)
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (6)
2004
-
12-Month comorbidity patterns and associated factors in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatrica Scandinavica, Supplement, Vol. 109, Núm. 420, pp. 28-37
-
Disability and quality of life impact of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatrica Scandinavica, Supplement, Vol. 109, Núm. 420, pp. 38-46
-
Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatrica Scandinavica, Supplement, Vol. 109, Núm. 420, pp. 21-27
-
Psychotropic drug utilization in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatrica Scandinavica, Supplement, Vol. 109, Núm. 420, pp. 55-64
-
Sampling and methods of the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatrica Scandinavica, Supplement, Vol. 109, Núm. 420, pp. 8-20
-
Use of mental health services in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project
Acta Psychiatrica Scandinavica, Supplement, Vol. 109, Núm. 420, pp. 47-54